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Abstract: Acute exacerbations of chronic obstructive pulmonary disease (COPD) are important 
events in the history of this debilitating lung condition. Associated health care utilization and 
morbidity are high, and many patients require supplemental oxygen or ventilatory support. The 
last 2 decades have seen a substantial increase in our understanding of the best way to manage 
the respiratory failure suffered by many patients during this high-risk period. This review article 
examines the evidence underlying supplemental oxygen therapy during exacerbations of COPD. 
We first discuss the epidemiology and pathophysiology of respiratory failure in COPD during 
exacerbations. The rationale and evidence underlying oxygen therapy, including the risks when 
administered inappropriately, are then discussed, along with further strategies for ventilatory 
support. We also review current recommendations for best practice, including methods for 
improving oxygen provision in the future.
Keywords: chronic obstructive pulmonary disease (COPD), exacerbation, oxygen therapy, 
respiratory failure, hypercapnia
Introduction
Chronic obstructive pulmonary disease (COPD) is a global health problem 
and is expected to be the third leading cause of mortality worldwide by 2020.1 
It is  characterized by persistent airflow limitation and acute episodes of symptom 
worsening, or exacerbations, that are beyond normal daily variation and that lead to 
a change in treatment.1 Acute exacerbations of COPD are key events and are associ-
ated with faster lung function deterioration,2 worsened health status,3 and increased 
mortality.4,5 Impaired gas exchange leading to hypoxemia is an important feature of 
COPD6 and is likely to underlie many of its pathophysiological consequences.
While the use of supplemental oxygen in stable disease carries a poor prognosis,7 
it remains one of the few evidence-based interventions to improve mortality.  However, 
although hypoxemia worsens at exacerbation,8 there is increasing evidence that 
 injudicious use of oxygen is also dangerous.
This review article will examine the pathophysiology and clinical features of 
hypoxemia in exacerbations of COPD, as well as the evidence and recommendations 
for supplemental oxygen therapy.
Definitions
Oxygen therapy is defined as oxygen given at concentrations greater than that found in 
the surrounding air. It is used as a treatment for respiratory failure, itself defined as an 
inability of the lungs and respiratory apparatus to ensure adequate systemic oxygenation 
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and/or carbon dioxide excretion. This is further classified by 
whether there is a failure of oxygenation (a low partial pressure 
of oxygen [PaO
2
]) with a normal partial pressure of carbon 
dioxide (PaCO
2
, “type 1” respiratory failure), or whether the 
PaCO
2
 is high (“type 2,” or hypercapnic, respiratory failure). 
Another important variable is whether acidosis is present as a 
consequence of hypercapnia, suggesting an acute worsening 
without time for compensation via the renal axis, which usually 
occurs over hours to days. The general principles and detailed 
pathophysiology of respiratory failure are beyond the scope 
of this article, but are well reviewed elsewhere.9
The usual arterial oxygen saturation (SaO
2
) for a young 
adult breathing air at sea level is 94%–98%,  corresponding 
to 11.98–14.82 kPa (89.3–110.5 mmHg), although this 
decreases with increasing age such that the range for 
those .64 years is 9.02–14.76 kPa (67.3–110.1 mmHg).10 
While hypoxemia may be defined as any arterial PaO
2
 
below the normal lower limit, most authors suggest a 
value of ,8 kPa (60 mmHg), or SaO
2
 ,90%, as clinically 
hypoxemic because the risk of hypoxic tissue damage increases 
below this level.9 The normal range for PaCO
2
 is 4.6–6.1 kPa 
(34–46 mmHg) and type 2 respiratory failure is diagnosed where 
hypercapnia is present, even in the absence of hypoxia.9
Prevalence and burden of chronic 
respiratory failure in COPD
The prevalence of supplemental oxygen used for respiratory 
failure in stable COPD is difficult to quantify and varies widely 
according to the population studied. In clinical trials recruiting 
patients with moderate disease (forced expiratory volume in 
1 second of ,70% predicted) the prevalence of oxygen use 
was 2%–4%;11,12 by contrast, in the National Emphysema 
Treatment trial it was used by .80% of patients with severe 
disease.13 However, there are few studies that assess unselected 
patients in primary care, and the true prevalence is likely to 
be much lower than this. One audit of COPD patients in the 
United Kingdom reported respiratory failure or cor pulmonale 
in only five of 397 patients, suggesting a prevalence closer to 
1% in the wider COPD population.14 Despite this, long-term 
oxygen therapy still accounts for an estimated specific health 
care expenditure of $2.3 billion/year in the United States 
alone, while the estimated $1.8 billion cost of hospitalization 
and emergency visits will also be due in part to the need for 
acute oxygen therapy at exacerbation.15
Respiratory failure during acute 
exacerbations of COPD
Although most patients with stable disease are able to 
 maintain acceptable parameters, decompensation and 
 respiratory failure are much more common in patients 
hospitalized with exacerbations. In a well-characterized 
Spanish cohort of 2,487 patients attending the emergency 
department with an acute exacerbation of COPD, 50% were 
hypoxemic at presentation (SaO
2
 ,90%) and 57% had a 
PaCO
2
 of .45 mmHg.7 In a UK audit of 9,716 patients from 
232 hospitals, 20% had respiratory acidosis at presentation.16 
Oxygen therapy is not always administered appropriately, 
however, with 24% of patients in one series being hyperox-
emic on arrival to hospital;17 this will be discussed further. 
Data from milder community-treated exacerbations are 
scarce, although an observational study of outpatients treated 
for exacerbations from the United Kingdom found a mean 
drop of only 1% in oxygen saturations,18 which reflects the 
fact that exacerbations with hypoxemia are more severe and 
usually treated in hospital.
Pathophysiology of respiratory 
failure at COPD exacerbation
Gas exchange in COPD is complex and influenced by a 
number of processes, although the principal common out-
come is a disruption of the normal ventilation–perfusion 
(V/Q) ratio in the lungs, such that the blood returning to the 
left atrium remains poorly oxygenated. This results in sys-
temic hypoxemia, while alveolar hypoventilation may also 
result in poor elimination of carbon dioxide and consequent 
hypercapnia.
The optimum V/Q ratio for gas exchange is 0.8, although 
even in health there is a gravitational gradient such that the 
ratio is higher at the top than the bottom of the lung. Different 
pathological processes in COPD have opposing effects on 
the V/Q ratio.19 For example, emphysematous areas of lung 
continue to receive adequate ventilation even though the 
alveolar capillary networks are destroyed; the physiological 
dead space prevents any significant benefit from the high V/Q 
ratio. Conversely, small airway inflammation and obstruc-
tion prevent adequate alveolar ventilation, reducing the V/Q 
ratio and potentially causing veno–venous  shunting. COPD 
is a heterogeneous lung condition and different pathological 
processes predominate in different lung areas, leading to 
admixture of differentially oxygenated blood on return to 
the systemic circulation.19
A complex series of events occurs at COPD exac-
erbation, worsening V/Q mismatch and oxygenation. 
 Consequent to an exacerbation trigger, usually viral 
or bacterial,20 airway inflammation increases rapidly,21 
causing increased mucus secretion, mucosal edema, and 
bronchospasm.22 This causes acute worsening of expiratory 
airflow limitation, which,  combined with tachypnea, leads to 
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a damaging cycle of dynamic hyperinflation and  abnormal 
breathing.23 These, along with other factors discussed below, 
markedly reduce alveolar ventilation. Changes within the 
pulmonary vasculature compound the situation. Pulmonary 
vascular resistance and pulmonary arterial pressure rise 
acutely at exacerbation24 and this, combined with cardiac 
dysfunction,25 reduces blood flow to the alveolar capillary 
bed. Despite this, perfusion appears to be disproportionately 
increased through poorly ventilated lung units,8 and this 
worsens systemic hypoxemia still further. These processes 
are summarized in Figure 1.
Hypercapnia is also an important consequence of alveo-
lar hypoventilation in severe COPD. While most patients 
are able to increase their respiratory drive and minute vol-
ume to maintain sufficient alveolar ventilation in the stable 
state,22 these adaptive mechanisms can easily be overcome 
at exacerbation by the pathological processes outlined 
above. The presence of decompensated hypercapnia causes 
respiratory acidemia, which normalizes over hours to days 
via the buffering action of bicarbonate ions generated by 
the kidney.26 This carries a poor prognosis27 related to the 
degree of acidemia28 and that appears to be worse if the 
hypercapnia persists after exacerbation recovery than if it 
reverts to normal.29
In addition to the underlying COPD, other comor-
bidities that may be present also affect hypoxemia at 
exacerbation. Disordered sleep is common in COPD 
patients, and many experience nocturnal oxygen 
 desaturation even in the absence of daytime hypoxemia.30 
The reported  prevalence of obstructive sleep apnea (OSA) 
in COPD (the so-called “overlap” syndrome)31 is similar 
to that in the general population at approximately 1%,32 
although it appears to carry a worse prognosis than COPD 
alone. Patients with the overlap syndrome had greater 
sleep desaturation33 and all-cause mortality,34 and reported 
more exacerbations of COPD, than did patients with either 
of these conditions alone. The etiology is likely multifac-
torial. There is a decrease in functional residual capacity 
when lying supine,35 and this, combined with increased 
airway resistance and reduced respiratory muscle tone, 
results in closing of small airways in dependent areas 
of lung. Although these changes occur physiologically 
to a small degree, they are much more marked in OSA. 
In patients with coexistent COPD, the added insult is 
sufficient to worsen V/Q mismatch and hypoxia, while 
further alveolar hypoventilation leads to reduced carbon 
dioxide excretion and hypercapnia. There is limited data 
on the effect of the overlap syndrome on exacerbations; 
however, recognition of OSA in these patients is impor-
tant, as there is evidence that appropriate treatment with 
noninvasive ventilation improves mortality36 and may 
prevent exacerbations.34 These patients may be more prone 
to develop hypercapnia at exacerbation, and therefore 
careful titration of oxygen therapy is also necessary, as 
discussed further below.
Cardiac dysfunction is also common at exacerbation 
and is often underrecognized. In a series of 242 patients 
hospitalized with COPD in Scotland, .10% fulfilled diag-
nostic criteria for myocardial infarction with raised cardiac 
enzymes, chest pain, or electrocardiogram changes when 
fully assessed.37 In a separate series, subclinical echocardio-
graphic abnormalities were present in 64% of 342 patients 
following first hospitalization for COPD;25 right ventricular 
enlargement (30%) and pulmonary hypertension (19%) 
were the most-common single abnormalities, although left 
heart abnormalities were present in 27% of patients. There 
is a high prevalence of cardiac failure in COPD,38 and the 
biochemical markers of cardiac dysfunction, brain natri-
uretic peptide (BNP) and troponin T, predict mortality after 
hospitalized exacerbations.39,40 In addition, patients who 
experience frequent COPD exacerbations have increased 
cardiovascular risk, which worsens further at exacerbation,41 
and this underlines the poor prognosis conferred by recurrent 
exacerbations. Cardiac dysfunction is therefore common 
and will also contribute to hypoxemia; this is important to 
recognize so that treatment can be optimized.
Worsened airflow limitation
Increased airway inflammation
Dynamic hyperinflation
Altered pulmonary hemodynamics
Reduced hypoxic inspiratory drive
Alveolar hypoventilation
Exacerbation
Stable COPD
Emphysema
Background airway inflammation
Poor functional reserve
Compensated V/Q mismatch Exacerbation triggers
Viruses
Bacteria
Environmental
Comorbidities
Obesity
Overlap syndrome
Cardiac dysfunction
Worsened V/Q mismatch
Respiratory failure
Figure 1 Pathological processes underlying the worsening of respiratory failure at 
COPD exacerbation.
Abbreviations: COPD, chronic obstructive pulmonary disease; v/Q, ventilation–
perfusion ratio.
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Acute exacerbation of COPD is a clinical diagnosis, and it 
is important to exclude other conditions causing hypoxia and 
respiratory failure. For example, pulmonary embolism may 
be present in up to a fifth of patients presenting to hospital 
with COPD exacerbation,42 and this may worsen hypoxemia 
by causing further V/Q mismatching. Other conditions caus-
ing acidosis, reduced tissue perfusion, or increased tissue 
oxygen requirements, notably systemic sepsis or cardiogenic 
shock, may also worsen respiratory failure in COPD patients 
and should be treated appropriately.
Beneficial effects of oxygen  
therapy in stable COPD
Aside from relieving the hypoxia associated with COPD, 
 supplemental oxygen therapy also reduces symptoms of 
dyspnea both in normal subjects and in those with severe 
COPD.43,44 A recent Cochrane meta-analysis including 
431 patients across 18 studies also showed a highly sig-
nificant improvement in dyspnea in nonhypoxemic COPD 
patients who would not otherwise meet physiological cri-
teria for oxygen therapy.45 Breathing supplemental oxygen 
versus compressed air improved dyspnea and endurance 
during exercise in COPD patients46 and, in those patients 
who showed an improvement in exercise tolerance fol-
lowing long-term oxygen therapy (LTOT), cardiac output 
was also increased.47 These effects are likely related to 
decreased minute ventilation48,49 and decreased dynamic 
 hyperinflation.50 Hypoxic pulmonary vasoconstriction and 
pulmonary hemodynamics may also be improved,46 leading 
to increased systemic oxygen delivery and improved respira-
tory muscle function.49 In addition, the flow of oxygen may 
stimulate upper airway and facial receptors, and this appears 
to reduce the intensity of dyspnea.51
Importantly, LTOT was the first therapy to demonstrate 
a reduction in mortality for COPD. Published in 1980, the 
Nocturnal Oxygen Therapy Trial52 randomized 203 patients 
with hypoxemic chronic lung disease to receive supple-
mental oxygen therapy, either continuously or overnight 
only, with follow-up for a minimum of 12 months. Oxygen 
therapy was given via nasal prongs with flow titrated to the 
minimum amount between 1–4 L/minute that produced a 
rise in PaO
2
. All-cause mortality in the continuous-treatment 
group was 52% of that in the nocturnal-only treatment group, 
with the difference even more marked in the subgroup 
with baseline hypercapnia. Shortly afterwards, the British 
Medical Research Council trial in the United Kingdom53 
published results from 87 patients with severe COPD and 
hypoxemia, hypercapnia, and congestive cardiac failure 
who were  randomized to receive oxygen (via nasal prongs 
at 2 L/minute, for a  minimum of 15 hours per day) or no 
oxygen therapy. After 5 years of follow-up, 30/45 (67%) of 
the untreated patients had died, compared to 19/42 (45%) of 
those who were given oxygen; arterial carbon dioxide tension 
and red-cell mass appeared to be useful predictors of poor 
prognosis. Together, these trials provide the evidence under-
lying the indications for the use of LTOT in severe COPD, 
as well as the recommendation to use LTOT for a mini-
mum of 15 hours/day to ensure maximal benefit. However, 
a further trial of LTOT in patients with milder hypoxemia 
(PaO
2
 ,8 kPa [60 mmHg]) showed no mortality benefit.54 
Therapy with LTOT should therefore be restricted to hypox-
emic patients with PaO
2
 ,7.3 kPa (55 mmHg), or ,8 kPa 
(60 mmHg) in the presence of complications including pul-
monary hypertension, polycythemia, or peripheral edema.55 
“Ambulatory” oxygen therapy may also be given to patients 
for use during exercise or activities of daily living, and while 
short-term studies show improved exercise performance in 
COPD,56 no survival benefit has been demonstrated.
Uncertainty remains regarding the use of LTOT in patients 
with isolated exercise desaturation, or only moderate hypox-
emia at rest, and given the scale of LTOT use in COPD there 
is therefore a pressing need for further evidence. It is hoped 
that the Long-term Oxygen Treatment Trial,57 which aims 
to recruit over 1,000 participants with COPD and moderate 
resting hypoxemia or exercise desaturation, will answer some 
of these questions.
Oxygen therapy at acute 
exacerbation of COPD
Supplemental oxygen delivered at moderate concentrations 
is usually adequate to overcome the hypoxia associated 
with COPD exacerbations, with the main risk being the 
long-recognized induction of hypercapnia.58 Despite this, 
high-flow oxygen has long been the standard treatment for 
acutely distressed patients, and until relatively recently this 
was also the case in COPD, especially in prehospital care. 
However, the risks of injudicious oxygen administration in 
these patients are now well recognized. We outline here the 
rationale and guidance for the appropriate use of oxygen 
during COPD exacerbations, as well as strategies for oxygen 
delivery and ventilatory support.
Oxygen-induced hypercapnia  
and hyperoxia at COPD exacerbation
One important consequence of oxygen therapy is a worsen-
ing of hypercapnia in susceptible patients, and this has long 
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been recognized. In 1949, case reports were first published 
of patients with chronic cor pulmonale in whom administra-
tion of high concentrations of oxygen induced neurological 
changes, including fatal coma and transient increases in 
intracranial pressure;59 hypercapnia was hypothesized to 
result from reduced minute ventilation (VE) resulting from 
reduced hypoxic stimulus to breathe.60 This widely held view 
was challenged by a study of patients with severe COPD 
and hypercapnia before and after breathing in 100% oxygen 
for 20 minutes.61 Although VE decreased transiently, after 
15 minutes it was again similar to control values on room air; 
despite this, there was a significant rise in PaCO
2
 values that 
was not correlated to changes in VE, and this was attributed to 
increased V/Q mismatching within the lungs, possibly due to 
the reversal of hypoxic vasoconstriction increasing perfusion 
of poorly ventilated lung units. However, this was investi-
gated more recently using the multiple inert-gas elimination 
technique in 22 patients during an exacerbation of COPD.62 
Intrapulmonary V/Q defects were similar in the 12 patients 
who developed hypercapnia with supplemental oxygen as in 
those who did not, although alveolar dead space increased 
in the hypercapnic patients. Importantly, VE also fell by 
approximately 20% in the hypercapnic patients. Respiratory 
muscle fatigue, also thought to be a factor, appears now to 
only occur at a late stage, and reductions in ventilation may 
also reflect a shallower breathing pattern.58
A further potential mechanism underlying oxygen-induced 
hypercapnia results from changes in the CO
2
–hemoglobin 
dissociation curve as the PaO
2
 increases. Oxygenated hemo-
globin has a lower carbon dioxide binding capacity than does 
deoxygenated hemoglobin, and as the proportion of oxygen-
ated hemoglobin increases there is a consequent rightward 
shift of the CO
2
–hemoglobin dissociation curve.63 This is 
known as the Haldane effect, and it results in an increase in 
PaCO
2
. While this is usually overcome by increasing VE, 
patients with severe COPD are often unable to do this and 
hypercapnia may worsen. This may explain up to 25% of the 
total PaCO
2
 increase due to oxygen administration.61
Oxygen-induced hypercapnia at COPD exacerbation 
is therefore due to a complex combination of factors and 
remains incompletely understood. The associated risk, how-
ever, is now well recognized. Many studies have focused 
on the oxygen therapy given at the point of prehospital 
care, usually by a treating paramedic crew during assess-
ment and transport to hospital, and this appears to be par-
ticularly important. In a retrospective case series of nearly 
1,000 patients in the United Kingdom, 20% had respiratory 
acidosis on presentation to hospital and this was associated 
with an increased risk for subsequent tracheal intubation.64 
The pH was inversely correlated with the PaO
2
, and more 
than half of hyperoxemic patients (PaO
2
 .13.3 kPa) were 
acidotic, reflecting the role of overoxygenation in the 
 prehospital setting. Where respiratory acidosis is present, 
the degree of acidosis correlates to mortality.65 Similarly, 
one retrospective audit of prehospital oxygen therapy given 
to 211 patients with acute exacerbations of COPD found 
that those treated with oxygen at a concentration of $28% 
were significantly more acidotic, with significantly higher 
partial pressures of carbon dioxide, than those in whom 
controlled oxygen therapy was administered.66 In one series 
of 254 patients presenting via ambulance with acute COPD 
exacerbation,17 hyperoxemia at presentation carried an odds 
ratio of 9.17 (95% confidence interval [CI] =4.08–20.6) over 
normoxemia for a composite of serious adverse outcomes 
(including hypercapnic respiratory failure), compared to only 
2.16 (95% CI =1.11–4.20) for hypoxemia. Further indirect 
evidence is provided by a large anonymized audit of arterial 
blood gas samples in hospital, which found oxygen satura-
tions above the recommended 92% in 72% of hypercapnic 
samples, suggesting that oxygen control is poor.67 Although 
hypoxia may be more acutely dangerous than hypercapnia, 
hyperoxia therefore also carries significant excess risk.
A further consideration in hypercapnic patients treated 
with high oxygen concentrations is the phenomenon of 
rebound hypoxia upon withdrawal of supplemental oxygen. 
This occurs because oxygen and carbon dioxide displace 
each other from the limited space within the alveoli accord-
ing to their relative partial pressures, as described by the 
alveolar gas equation.9 In the presence of a very high  alveolar 
PaO
2
 (as seen when breathing a high concentration of 
supplemental oxygen), systemic oxygenation is maintained 
even as the PaCO
2
 rises to a level higher than it was when 
the patient was breathing room air. The human body stores 
more carbon dioxide than oxygen, and if the supplemental 
oxygen is abruptly withdrawn there may be a sharp fall in 
the alveolar PaO
2
 as the remaining carbon dioxide displaces 
the (now lower-pressure) oxygen. The result is a fall in arte-
rial PaO
2
, which can be precipitous and may cause death by 
acute arterial hypoxemia even though the PaCO
2
 is stable or 
improving.68 For this reason, oxygen therapy should always 
be stepped down gradually.9
Despite compelling observational data, until relatively 
recently there has been a lack of high-quality evidence to 
directly demonstrate the benefits of titrated oxygen therapy 
over high-concentration oxygen. In 2010, Austin et al69 
carried out the first large, well-conducted study of titrated 
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oxygen therapy in prehospital care for suspected COPD 
exacerbations. In a cluster randomized trial, with individual 
paramedics as the unit of randomization, titrated oxygen 
therapy (via nasal prongs with the goal of maintaining satura-
tions between 88%–92%; 32 paramedics) or the standard care 
of high-flow oxygen delivered via face mask (30 paramedics) 
was administered to patients; 214 patients were included in 
the intent-to-treat analysis, with 97 in the titrated-oxygen 
arm and 117 in the high-flow oxygen arm. In spite of lapses 
in adherence to the oxygen-titration protocol, there was a 
78% reduction in mortality for those patients with confirmed 
COPD, as well as reduced rates of respiratory acidosis and 
hypercapnia.
There is now therefore strong evidence that titrating oxy-
gen therapy to alleviate hypoxia while avoiding hyperoxia 
is the correct approach to oxygen therapy in COPD patients 
who are at high risk of hypercapnic respiratory acidosis. 
Until these patients are identified by arterial blood gas 
analysis, titrating oxygen therapy in all patients is prudent.
Administration of oxygen therapy
The key to achieving appropriate levels of oxygenation is 
using controlled oxygen therapy, with the patient’s oxy-
gen level monitored and the supplemental oxygen therapy 
titrated to achieve acceptable saturations. This approach is 
summarized in Figure 2. Titration can be achieved either 
by altering the oxygen flow rate or, with certain delivery 
devices, administering a mixture of air and oxygen in set 
proportions such that the patient breathes in a known fraction 
of inspired oxygen (FiO
2
). The principal modes of delivery 
are described below.
Nasal cannulae are perhaps the simplest mode of adminis-
tering low-to-moderate concentrations of inspired oxygen and 
have considerable advantages over standard face masks. The 
Select target
SaO2 range
Select oxygen
delivery device
94%–98% (no hypercapnia risk)
88%–92% (at risk of hypercapnia)
Apply oxygen
therapy
SaO2 too low SaO2 too high
Up-titrate
oxygen therapy
Down-titrate
oxygen therapy
Consider further ventilatory
strategies
Reassess patient
Unable to achieve
target SaO2 range
Figure 2 General principles of titrated oxygen therapy.
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short cannulas deliver oxygen directly to the  nasopharynx, 
reducing dead space and inspiratory resistance, and they 
can deliver a range of oxygen flow rates from 1–6 L/minute, 
corresponding to FiO
2
 values of  approximately 24%–50%.9 
No face mask is required and patients can therefore eat and 
speak while wearing their oxygen, and the cannulas are less 
likely than face masks to fall off or become dislodged by 
facial movement.70 Unsurprisingly, patients prefer cannulas 
to face masks, and this improves compliance with oxygen 
therapy.71 In addition, low-flow oxygen therapy can be contin-
ued via nasal cannulas during the administration of air-driven 
nebulizers for hypercapnic or acidotic patients.55 However 
there are also disadvantages to nasal cannulas. Some patients 
experience nasal dryness or discomfort, particularly at higher 
flow rates. In addition, the FiO
2
 is affected by a multitude of 
patient factors, including mouth breathing, degree of nasal 
congestion, and the respiratory rate and minute volume. 
These factors may also change in the same patient at different 
times (for example, while eating). The use of nasal cannulas 
should therefore target a specific oxygen saturation level, with 
ongoing monitoring and titration of the oxygen flow rate to 
achieve this. Nasal cannulas are not recommended for the 
acutely unwell COPD patient, in whom accurate control of 
FiO
2
 is critical.9 However, once stability is achieved, nasal 
cannulas with oxygen flow rates titrated to target oxygen satu-
rations represent the simplest and most-acceptable method 
of administering controlled oxygen therapy.
Simple face masks are able to deliver a higher con-
centration of inspired oxygen than nasal cannulas, usually 
between 40%–60%. The exact FiO
2
 is highly variable, how-
ever, and there is a risk of rebreathing carbon dioxide at low 
flow rates. In addition, the concentration of O
2
 administered 
is inversely related to minute volume; if this falls and the 
oxygen flow rate remains constant (for example if the patient 
becomes drowsy due to oxygen-induced CO
2
 narcosis), the 
concentration of oxygen inspired via the mask will increase, 
further exacerbating the problem. These problems can be 
partially circumvented by using a non-rebreathing face mask, 
which has an oxygen reservoir bag attached; at high oxygen 
flow rates an FiO
2
 of 60%–90% can be delivered. Even here, 
however, the exact FiO
2
 is highly variable and dependent on 
the patient’s minute volume. Even in COPD exacerbations, 
oxygenation to a safe level is usually achievable with an FiO
2
 
of ,60%, and for this reason these masks are not recom-
mended for patients at risk of hypercapnic respiratory failure 
where controlled oxygen therapy is necessary.9
In 1960, Moran Campbell introduced a simple system that 
was able to entrain air into an oxygen stream across differing 
flow rates, with the amount of air added increasing as the flow 
of oxygen increased but the proportions remaining equal.72 
Although the risks of excess oxygen therapy in patients with 
cor pulmonale had been well recognized, up to this point 
oxygen therapy could only be controlled by giving it intermit-
tently alternated with periods on room air, a practice likened to 
“bringing a drowning man to the surface – occasionally.”73 The 
Venturi system, as it came to be known, allowed the constant 
delivery of a fixed concentration of oxygen to the patient. 
Crucially, this could be delivered at higher flow rates for tac-
hypneic patients in whom the minute volume might otherwise 
exceed the available oxygen flow. Each valve is manufactured 
to deliver only a specific FiO
2
, with valves for 24%, 28%, 
35%, 40%, and 60% usually available, and a minimum oxygen 
flow rate, above which the resulting air–oxygen mixture will 
correspond to the intended ratios, is specified. The Venturi 
system must be used with a face mask and therefore is subject 
to the usual disadvantages, including intrusiveness to patients, 
preventing eating and conversation, and being more prone 
to dislodge, but remains the preferred method for controlled 
oxygen administration in the emergency situation.9
The principle of controlled oxygen therapy is to target 
the patient’s oxygen saturations within a range rather than at 
a specific FiO
2
. This is because the patient factors affecting 
SaO
2
 are dynamic and will change over time; a fixed FiO
2
 
will not be responsive to these changing demands. Oxygen 
levels should be maintained at a safe level while avoiding 
hyperoxemia that would increase the risk of hypercapnia. 
Historically, there has been some debate as to what a “safe” 
level of hypoxemia is. Early investigators reported memory 
loss and cognitive difficulties in normal subjects at PaO
2
 
levels ,45 mmHg (6.0 kPa),74 with levels ,20 mmHg 
(2.7 kPa) incompatible with life.75 Patients with COPD are 
able to acclimatize to even quite a severe degree of chronic 
hypoxia, however, and maintaining PaO
2
 .50 mmHg 
(6.7 kPa) is sufficient to prevent immediate death,76 although 
oxygen therapy should aim to maintain a safe level above this 
in order to preserve normal cognitive function and prevent 
transient desaturations.76 The usual lower PaO
2
 limit for 
targeted oxygen therapy is 55 mmHg (7.3 kPa), used as the 
entry criteria for the LTOT trials and subsequently ratified by 
consensus committee.77 In practice, real-time monitoring of 
PaO
2
 is not usually possible and therefore a target SaO
2
 range 
of 88%–92% is now generally accepted for those patients 
at risk of hypercapnia. Allowing for individual variations 
in the oxygen dissociation curve, this will correct hypoxia 
to a safe level and minimize the risk of oxygen-induced 
hypercapnia.
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Hypercapnia at COPD exacerbation is unusual in that it 
does not occur in all patients, even those with resting baseline 
hypercapnia; some patients may suffer recurrent hypercapnic 
episodes while others may only ever have isolated  hypoxemia. 
Without arterial blood gas analysis, identifying those patients 
with hypercapnia is not possible. For this reason, current 
clinical guidance recommends that all patients with respira-
tory failure in the context of a diagnosis or history suggestive 
of COPD receive oxygen therapy targeted to 88%–92% until 
hypercapnia has been excluded by arterial blood gas analysis.9 
Some patients are extremely oxygen-sensitive, with even very 
small amounts of supplemental oxygen sufficient to worsen 
hypercapnia, and these patients may need a lower target 
saturation range. However, if the PaCO
2
 is normal, oxygen 
therapy may target the usual saturation range of 94%–98%, 
although many COPD patients may have a lower stable SaO
2,
 
such that chasing this target is not usually necessary unless 
the patient is unwell.
Following initiation of oxygen therapy, close observation 
and reassessment of the patient is key. Patients suffering 
acute COPD exacerbations can be extremely unwell and, 
particularly in the early stages following presentation, their 
condition can change extremely quickly. Regular assessment 
should include not only their respiratory rate, oxygen satura-
tions, and other physiological measurements, but also their 
conscious level, as any depression of consciousness may 
suggest incipient carbon dioxide narcosis. As the patient 
improves, the oxygen should be reduced such that the upper 
limit of the target range is not breached. Supplemental oxygen 
therapy should be treated as a medication and prescribed on 
the treatment chart in the same way as other pharmacological 
agents. Prescriptions should include information regarding 
the delivery device, oxygen flow rate, and target oxygen 
saturation range, with instructions on what action to take if 
these parameters are exceeded in either direction.
It is important to remember that oxygen therapy during 
acute exacerbations of COPD is a supportive measure only 
and must be accompanied by treatment of the underlying 
COPD exacerbation. In most cases this will involve inhaled 
or nebulized bronchodilators, antibiotics, and systemic 
 corticosteroids, as appropriate.55
Further ventilatory strategies
Unless the patient is in extremis, adequate oxygenation 
using one of the methods above is usually possible for 
COPD patients who have type I respiratory failure without 
 hypercapnia. However, the patient with hypercapnic respi-
ratory failure and acidosis may prove more complicated, 
and  hypercapnia may progress despite treatment of the 
 exacerbation and adequately controlled oxygen therapy. 
In these patients it may become impossible to adequately 
maintain even minimal oxygenation without further hyper-
capnia and potential coma, and further ventilatory support 
may be needed.
The respiratory stimulant doxapram has been used for 
many years as a means of avoiding endotracheal intuba-
tion and invasive positive-pressure ventilation. It works via 
stimulation of central and peripheral chemoreceptors, with 
the result of increasing tidal volume and minute ventilation.78 
This improves the excretion of carbon dioxide, allowing 
correction of hypoxia without worsening hypercapnia. 
However, the pharmacokinetics are not predictable and 
therefore a constant infusion is required, with titration to 
dose response. It is slightly better than placebo at prevent-
ing blood-gas deterioration in the first hours of therapy,79 
but has since been superseded by noninvasive ventilation 
(NIV). Doxapram is now recommended for use only when 
NIV is not available.55
Until NIV was introduced, endotracheal intubation and 
mechanical ventilation was the only remaining option for 
patients who failed best medical therapy. This carries significant 
risk, and many patients with very severe underlying COPD are 
deemed too frail to undergo the procedure. There has therefore 
long been a need for methods of ventilatory support that avoid 
the need for sedation and intubation. Noninvasive ventilators 
were developed in the 1980s to deliver positive airway pres-
sure via a face mask, and these may either be pressure preset 
to deliver differential pressures in inspiration and expiration, 
or be volume preset to deliver specific volumes.80,81 The pres-
sure is delivered by air compression, and supplemental oxygen 
may also be administered; newer devices are able to deliver a 
specified oxygen concentration, while other devices entrain 
oxygen with the air, resulting in a variable but unknown oxygen 
concentration. Nebulized bronchodilators may also be adminis-
tered through the tubing, and the apparatus has now evolved to 
be portable and simple to use. The mode of action is multifac-
torial and involves resting of the respiratory muscles, reversal 
of atelectasis with recruitment of lung units, and improved 
tidal volume.82 The net result is an increase in minute volume 
and reduction in the work of breathing, with increased carbon 
dioxide excretion and reversal of hypercapnia.83
Early reports in acute COPD exacerbations showed that, 
compared to historical controls, the apparatus was effective 
at reducing PaCO2, improving aci dosis and oxygenation, 
and avoiding the need for mechanical ventilation.80 The first 
prospective randomized controlled trials followed shortly and 
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confirmed striking benefits of NIV in reducing intubation, length 
of hospital stay, and in-hospital mortality, as well as a host of 
physiological parameters, compared to standard treatment.84,85 
There is now a wealth of further evidence to support these 
conclusions,86 and NIV has become the accepted standard of 
care for patients with type 2 respiratory failure (pH ,7.35 and 
PaCO
2
 .6 kPa) due to acute exacerbation of COPD despite 
controlled oxygen and best medical treatment.87
NIV has many advantages. With appropriate expertise 
and a compliant patient, it is relatively simple to set up and 
allows the concurrent administration of oxygen and nebulized 
 bronchodilators. Although some patients are unable to toler-
ate the tight-fitting mask, most do manage and the apparatus 
allows for breaks to be taken for eating and other activities. 
There are some contraindications to the use of NIV, particularly 
for patients who are unable to maintain their own airway due 
to obstruction or reduced conscious level, in life-threatening 
hypoxemia, or in the presence of undrained pneumothorax.88 
However, in patients who would not be suitable candidates for 
endotracheal intubation and where NIV is the decided ceiling of 
care, it may be tried even in the presence of some of these con-
traindications. Regardless, clear contingency plans regarding 
whether or not to proceed to tracheal intubation in the event of 
treatment failure should always be in place prior to starting NIV, 
and those patients with severe respiratory acidosis (pH ,7.26) 
should be managed in a high-dependency area and with a low 
threshold for intubation if appropriate.87 More detailed guidance 
on the use of NIV is available elsewhere.87,88
Current guidance for oxygen therapy  
in acute exacerbations of COPD
As the risks and optimal strategies for oxygen therapy have 
become clearer, consensus guidelines have been written to 
formalize best practice. From the United Kingdom, the British 
Thoracic Society Guideline for emergency oxygen therapy9 
provides highly detailed guidance on the delivery of oxygen 
therapy in COPD and other conditions. Other national and 
international guidance statements on COPD, including those 
from the Global Initiative for Chronic Obstructive Lung 
 Disease (GOLD),89 American Thoracic Society and European 
Respiratory Society,90 and the National Institute for Clinical 
Excellence55 also include broad recommendations for the use of 
supplemental oxygen therapy during COPD exacerbations.
Current practice and strategies  
for changing behavior
The first step toward improving standards is to define the 
targets for optimal care. There are now nationally and 
 internationally agreed guidelines, described above, and this 
has allowed an assessment of current practice and identifica-
tion of targets for improvement.
The recent European COPD Audit91 examined in-hospital 
care against ten standards derived from the 2010 GOLD 
guidance on COPD management.89 Data were available 
from 384 hospitals in 13 countries, for 16,018 patients admitted 
with exacerbations of COPD. Of these, 85% of patients were 
given controlled oxygen therapy, 82% had arterial blood gas 
analysis performed on admission, and 51% received NIV as 
recommended, although there were wide regional variations. 
Although the delivery of NIV was highlighted as a specific 
area for improvement, controlled oxygen therapy was not 
correctly administered in a substantial number of cases. Even 
where oxygen is prescribed, deficiencies may still be  identified. 
A large multicenter audit of inpatient oxygen therapy in 
Portugal found that although oxygen was prescribed in 93% of 
cases, the majority specified a fixed flow rate rather than target 
oxygen saturations, and the prescription was only completed in 
12%; in any case, 23% of patients were not receiving the pre-
scribed therapy.92 It should be noted that these audits have only 
focused on the provision of oxygen after the patient is admitted 
to  hospital. Many patients are still given high concentrations of 
oxygen during prehospital care, arriving at hospital hyperox-
emic and/or hypercapnic,64–66 and it is in this acute setting that 
instituting correct oxygen management is most crucial.
The next logical step is to address how the provision 
of oxygen therapy for these patients may be improved. 
Simple interventions may change behavior: for example, 
in one retrospective series in England, issuing 28% Venturi 
masks to ambulance crews assisted in reducing the propor-
tion of patients receiving high-flow oxygen prehospital.66 
 Standardized care “bundles” have been shown to reduce mor-
tality across a variety of conditions by improving in-hospital 
care,93 and implementing a simple standardized package of 
recommendations for COPD exacerbations at the emergency 
department of one large teaching hospital significantly 
improved compliance with treatment guidelines, notably 
increasing the correct provision of oxygen therapy from 76% 
to 96%.94 In addition, the move toward comprehensively pre-
scribing oxygen should provide a simple framework to guide 
staff caring for the patient. Perhaps paramount, however, 
is the education of health care professionals, particularly 
the doctors, nurses, and paramedics who are responsible 
for administering oxygen therapy to patients with COPD.95 
Hospitals should institute local policies to improve education 
and practice, and these should be subject to rigorous audit 
and reevaluation.55
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Improving the education of patients may also be a factor. 
A recent study of patients hospitalized with COPD exacerba-
tions showed variable awareness of the symptoms leading up 
to an exacerbation, which delayed symptom reporting and 
may therefore have increased the severity at presentation.96 
In addition, patients who are known to be at risk of hyper-
capnic respiratory failure should be given oxygen “alert 
cards,”97 which warn any treating clinicians, particularly 
paramedics, that they should be given controlled rather than 
high-concentration oxygen therapy.9
Conclusion
There is clear evidence that the correct use of supplemental 
oxygen therapy during exacerbations of COPD is an impor-
tant factor that can strongly influence outcomes, and we 
have sought to outline this here. Future research may focus 
on new delivery strategies to improve the titration of oxygen 
therapy98 as well as new therapies to treat the underlying 
COPD. In the meantime, we must ensure that the knowledge 
already available is translated into clinical practice and that 
best practice is followed. This will undoubtedly improve the 
treatment given to these patients.
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